Vivos (RDGL) Cash from Financing Activities (2010 - 2025)
Vivos (RDGL) reported Cash from Financing Activities of -$845.0 for Q4 2025, down 100.06% on a YoY basis from $1.5 million in Q4 2024, and down 100.06% sequentially from $1.5 million in Q1 2025.
Vivos (RDGL) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Vivos (RDGL) has 15 years of Cash from Financing Activities data on file, last reported at -$845.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 100.06% year-over-year to -$845.0; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (down 34.6% YoY), and the FY2025 full-year result was $1.5 million, down 34.6% from the prior year.
- Cash from Financing Activities slipped to -$845.0 in Q4 2025, from $1.5 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $1.8 million in Q1 2021 to a low of -$145000.0 in Q4 2021.
- A 4-year average of $667335.9 and a median of $518580.0 in 2023 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 2420.16% in 2021, while the deepest fall reached 111.56% in 2021.
- Tracing RDGL's Cash from Financing Activities over 4 years: stood at -$145000.0 in 2021, then jumped by 457.64% to $518580.0 in 2023, then soared by 182.56% to $1.5 million in 2024, then slumped by 100.06% to -$845.0 in 2025.
- Business Quant data shows RDGL's Cash from Financing Activities at -$845.0 in Q4 2025, $1.5 million in Q1 2025, and $1.5 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.03 Bn | 175.74 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 129.38 Bn | 126.50 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 108.86 Bn | 99.64 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 68.57 Bn | 67.12 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 47.66 Bn | 43.99 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 28.64 Bn | 27.52 Bn | 750.30 Mn | -25.00 Mn |
| 7 | GE HealthCare Technologies | 28.55 Bn | 26.27 Bn | 1.98 Bn | 21.00 Mn |
| 8 | Smith & Nephew | 27.02 Bn | 26.44 Bn | - | - |
| 9 | Koninklijke Philips | 25.54 Bn | 22.42 Bn | 2.07 Bn | -26.93 Mn |
| 10 | Vivos | 27.57 Mn | 26.01 Mn | -3,105.00 | -845.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -845.00 |
| Dec 31, 2025 | -845.00 |
| Mar 31, 2025 | 1.51 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Jun 30, 2024 | 709,000.00 |
| Jun 30, 2024 | 709,000.00 |
| Mar 31, 2024 | 130,000.00 |
| Mar 31, 2024 | 130,000.00 |
| Dec 31, 2023 | 518,580.00 |
| Dec 31, 2023 | 518,580.00 |
| Sep 30, 2023 | 10,000.00 |
| Sep 30, 2023 | 10,000.00 |
| Dec 31, 2021 | -145,000.00 |
| Dec 31, 2021 | -145,000.00 |
| Mar 31, 2021 | 1.81 Mn |
| Mar 31, 2021 | 1.81 Mn |
| Dec 31, 2020 | 1.25 Mn |
| Dec 31, 2020 | 1.25 Mn |